5 Best Quality Stocks To Watch Right Now

5 Best Quality Stocks To Watch Right Now: Acorda Therapeutics Inc.(ACOR)

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally. Its lead research and development programs include three biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing Glial Growth Factor 2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelina ting Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. In addition, the company has in-licensed a clinical-stage program, AC105, to develop an acute treatment for neurological trauma. It has collaboration agreement with Biogen Idec International GmbH to develop and commercialize products containing aminopyridines to the treatment of MS. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Hawthorne, New York.

Advisors' Opinion:

• [By Eric Volkman]

  Acorda Therapeutics (NASDAQ: ACOR  ) today announced its selection of a newCFO. Michael Rogers replaces David Lawrence, who has been named chief of business operations.

• ! [By Jonas Elmerraji]

  Nearest Resistance: $40
  Nearest Support: $29
  Catalyst: Civitas Acquisition

  Small-cap biopharma firm Acorda Therapeutics (ACOR) made the most-actives list on Wednesday after the firm blasted 28% higher during the session on acquisition news. No, it wasn't Acorda that was getting acquired. Instead, ACOR announced that it was purchasing Civitas Therapeutics, the developer of an experimental Parkinson's disease treatment.

  The news broke ACOR out of a downtrend that had harangued shares since the first quarter, but that doesn't mean you should jump into this name just yet. Shares are within grabbing distance of an important resistance level at $40, a level that's swatted down ACOR's buying pressure in the past. At this point, it makes sense to wait to see if this name can catch a bid above $40 before buying here.

  Must Read: Warren Buffett's Top 10 Dividend Stocks

• [By Garrett Cook]

  Acorda Therapeutics (NASDAQ: ACOR) was down, falling 7.14 percent to $32.76 after the company announced a public offering of $300 million principal amount of convertible senior notes due 2021.

• [By RichardCox]

  With any rally, some examples of over-extension can be found. One stock to sell on the short side can be seen in Acorda Therapeutics (ACOR), which to some will look cheap with its low P/E ratio of 9.6. Looking at the fundamentals, product stories some potential obstacles. Looking at the walk-test data in the company's central offering (Ampyra) have been largely uninspiring. Because of this, further Phase IIb trials will likely be required before we can see a move into Phase III. This will almost certainly stall the development process - by as much as 2 years. This story will continue to drag on projections and create downward revisions in both sales growth and earnings projections and sales growth. Upside potential for this stock remains limited, and short selling opportunities await on any rallies:

source fr! om Top Stocks To Buy For 2015:http://www.topstocksforum.com/5-best-quality-stocks-to-watch-right-now-4.html